TY  - JOUR
A1  - Stölzel, F.
A1  - Mohr, B.
A1  - Kramer, M.
A1  - Oelschlägel, U.
A1  - Bochtler, T.
A1  - Berdel, W. E.
A1  - Kaufmann, M.
A1  - Baldus, C. D.
A1  - Schäfer-Eckart, K.
A1  - Stuhlmann, R.
A1  - Einsele, H.
A1  - Krause, S. W.
A1  - Serve, H.
A1  - Hänel, M.
A1  - Herbst, R.
A1  - Neubauer, A.
A1  - Sohlbach, K.
A1  - Mayer, J.
A1  - Middeke, J. M.
A1  - Platzbecker, U.
A1  - Schaich, M.
A1  - Krämer, A.
A1  - Röllig, C.
A1  - Schetelig, J.
A1  - Bornhäuser, M.
A1  - Ehninger, G.
T1  - Karyotype complexity and prognosis in acute myeloid leukemia
JF  - Blood Cancer Journal
N2  - A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients with acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ in the definition of unbalanced aberrations as well as the number of single aberrations. The aim of this study on 3526 AML patients was to redefine and validate a cutoff for karyotype complexity in AML with regard to adverse prognosis. Our study demonstrated that (1) patients with a pure hyperdiploid karyotype have an adverse risk irrespective of the number of chromosomal gains, (2) patients with translocation t(9;11)(p21∼22;q23) have an intermediate risk independent of the number of additional aberrations, (3) patients with 4 abnormalities have an adverse risk per se and (4) patients with three aberrations in the absence of abnormalities of strong influence (hyperdiploid karyotype, t(9;11)(p21∼22;q23), CBF-AML, unique adverse-risk aberrations) have borderline intermediate/adverse risk with a reduced overall survival compared with patients with a normal karyotype.
KW  - Cancer genetics
KW  - Genetics research
Y1  - 2016
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-164530
VL  - 6
ER  - 
TY  - JOUR
A1  - Röllig, C.
A1  - Kramer, M.
A1  - Gabrecht, M.
A1  - Hänel, M.
A1  - Herbst, R.
A1  - Kaiser, U.
A1  - Schmitz, N.
A1  - Kullmer, J.
A1  - Fetscher, S.
A1  - Link, H.
A1  - Mantovani-Löffler, L.
A1  - Krümpelmann, U.
A1  - Neuhaus, T.
A1  - Heits, F.
A1  - Einsele, H.
A1  - Ritter, B.
A1  - Bornhäuser, M.
A1  - Schetelig, J.
A1  - Thiede, C.
A1  - Mohr, B.
A1  - Schaich, M.
A1  - Platzbecker, U.
A1  - Schäfer-Eckart, K.
A1  - Krämer, A.
A1  - Berdel, W. E.
A1  - Serve, H.
A1  - Ehninger, G.
A1  - Schuler, U. S.
T1  - Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
JF  - Annals of Oncology
N2  - Background: The combination of intermediate-dose cytarabine plus mitoxantrone (IMA) can induce high complete remission rates with acceptable toxicity in elderly patients with acute myeloid leukemia (AML). We present the final results of a randomized-controlled trial comparing IMA with the standard 7+3 induction regimen consisting of continuous infusion cytarabine plus daunorubicin (DA). 

Patients and methods: Patients with newly diagnosed AML>60 years were randomized to receive either intermediate-dose cytarabine (1000 mg/m(2) twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m(2) days 1-3) (IMA) or standard induction therapy with cytarabine (100 mg/m(2) continuously days 1-7) plus daunorubicin (45 mg/m(2) days 3-5) (DA). Patients in complete remission after DA received intermediate-dose cytarabine plus amsacrine as consolidation treatment, whereas patients after IMA were consolidated with standard-dose cytarabine plus mitoxantrone. 

Results: Between February 2005 and October 2009, 485 patients were randomized; 241 for treatment arm DA and 244 for IMA; 76% of patients were >65 years. The complete response rate after DA was 39% [95% confidence interval (95% CI): 33-45] versus 55% (95% CI: 49-61) after IMA (odds ratio 1.89, P = 0.001). The 6-week early-death rate was 14% in both arms. Relapse-free survival curves were superimposable in the first year, but separated afterwards, resulting in 3-year relapse-free survival rates of 29% versus 14% in the DA versus IMA arms, respectively (P = 0.042). The median overall survival was 10 months in both arms (P = 0.513). 

Conclusion: The dose escalation of cytarabine in induction therapy lead to improved remission rates in the elderly AML patients. This did not translate into a survival advantage, most likely due to differences in consolidation treatment. Thus, effective consolidation strategies need to be further explored. In combination with an effective consolidation strategy, the use of intermediate-dose cytarabine in induction may improve curative treatment for elderly AML patients.
KW  - acute myeloid leukemia
KW  - cytarabine dose
KW  - elderly
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-226473
VL  - 29
IS  - 4
ER  - 
TY  - JOUR
A1  - Brixner, T.
A1  - Aeschlimann, M.
A1  - Fischer, A.
A1  - Geisler, P.
A1  - Goetz, S.
A1  - Hecht, B.
A1  - Huang, J. S.
A1  - Keitzl, T.
A1  - Kramer, C.
A1  - Melchior, P.
A1  - Pfeiffer, W.
A1  - Razinskas, G.
A1  - Rewitz, C.
A1  - Schneider, C.
A1  - Strüber, C.
A1  - Tuchscherer, P.
A1  - Voronine, D. V.
T1  - Coherent spectroscopies on ultrashort time and length scales
JF  - EPJ Web of Conferences
N2  - Three spectroscopic techniques are presented that provide simultaneous spatial and temporal resolution: modified confocal microscopy with heterodyne detection, space-time-resolved spectroscopy using coherent control concepts, and coherent two-dimensional nano-spectroscopy. Latest experimental results are discussed.
KW  - coherent spectroscopy
KW  - ultrashort time
KW  - length scale
Y1  - 2013
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-129073
VL  - 41
ER  - 
TY  - JOUR
A1  - Fritz, Melanie
A1  - Vanselow, Jens
A1  - Sauer, Nadja
A1  - Lamer, Stephanie
A1  - Goos, Carina
A1  - Siegel, T. Nicolai
A1  - Subota, Ines
A1  - Schlosser, Andreas
A1  - Carrington, Mark
A1  - Kramer, Susanne
T1  - Novel insights into RNP granules by employing the trypanosome's microtubule skeleton as a molecular sieve
JF  - Nucleic Acids Research
N2  - RNP granules are ribonucleoprotein assemblies that regulate the post-transcriptional fate of mRNAs in all eukaryotes. Their exact function remains poorly understood, one reason for this is that RNP granule purification has not yet been achieved. We have exploited a unique feature of trypanosomes to prepare a cellular fraction highly enriched in starvation stress granules. First, granules remain trapped within the cage-like, subpellicular microtubule array of the trypanosome cytoskeleton while soluble proteins are washed away. Second, the microtubules are depolymerized and the granules are released.

RNA sequencing combined with single molecule mRNA FISH identified the short and highly abundant mRNAs encoding ribosomal mRNAs as being excluded from granules. By mass spectrometry we have identified 463 stress granule candidate proteins. For 17/49 proteins tested by eYFP tagging we have confirmed the localization to granules, including one phosphatase, one methyltransferase and two proteins with a function in trypanosome life-cycle regulation.

The novel method presented here enables the unbiased identification of novel RNP granule components, paving the way towards an understanding of RNP granule function.
Y1  - 2015
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126180
ER  - 
TY  - JOUR
A1  - Braunschweig, Holger
A1  - Kramer, T.
T1  - Crystal structure of μ-1κC:2(\(η^2\))-carbonyl-carbonyl-1κC-chlorido-2κCl-μ-chloridoborylene-1:2\(κ^2\) B:B-[1(\(η^5\))-pentamethylcyclopentadienyl](tricyclohexylphosphane-2κP)iron(II)platinum(II) benzene monosolvate
N2  - In the mol­ecular structure of the dinuclear title compound \([η^5-(C_5(CH_3)_5)(CO)Fe{(μ-BCl)(μ-CO)}PtCl(P(C_6H_{11})_3)]·C_6H_6\), the two metal atoms, iron(II) and platinum(II), are bridged by one carbonyl (μ-CO) and one chlorido­borylene ligand (μ-BCl). The \(Pt^{II}\) atom is additionally bound to a chloride ligand situated trans to the bridging borylene, and a tri­cyclo­hexyl­phosphane ligand \((PCy_3)\) trans to the carbonyl ligand, forming a distorted square-planar structural motif at the \(Pt^{II}\) atom. The \(Fe_{II}\) atom is bound to a penta­methyl­cyclo­penta­dienyl ligand \([η^5-C_5(CH_3)_5]\) and one carbonyl ligand (CO), forming a piano-stool structure. Additionally, one benzene solvent mol­ecule is incorporated into the crystal structure, positioned staggered relative to the penta­methyl­cyclo­penta­dienyl ligand at the \(Fe^{II}\) atom, with a centroid–centroid separation of 3.630 (2) Å.
KW  - platinum
KW  - oxidative addition
KW  - borylene
KW  - heterodinuclear compound
KW  - crystal structure
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120120
VL  - 70
IS  - 11
ER  - 
TY  - JOUR
A1  - van Koolwijk, Leonieke M. E.
A1  - Ramdas, Wishal D.
A1  - Ikram, M. Kamran
A1  - Jansonius, Nomdo M.
A1  - Pasutto, Francesca
A1  - Hys, Pirro G.
A1  - Macgregor, Stuart
A1  - Janssen, Sarah F.
A1  - Hewitt, Alex W.
A1  - Viswanathan, Ananth C.
A1  - ten Brink, Jacoline B.
A1  - Hosseini, S. Mohsen
A1  - Amin, Najaf
A1  - Despriet, Dominiek D. G.
A1  - Willemse-Assink, Jacqueline J. M.
A1  - Kramer, Rogier
A1  - Rivadeneira, Fernando
A1  - Struchalin, Maksim
A1  - Aulchenko, Yurii S.
A1  - Weisschuh, Nicole
A1  - Zenkel, Matthias
A1  - Mardin, Christian Y.
A1  - Gramer, Eugen
A1  - Welge-Lüssen, Ulrich
A1  - Montgomery, Grant W.
A1  - Carbonaro, Francis
A1  - Young, Terri L.
A1  - Bellenguez, Céline
A1  - McGuffin, Peter
A1  - Foster, Paul J.
A1  - Topouzis, Fotis
A1  - Mitchell, Paul
A1  - Wang, Jie Jin
A1  - Wong, Tien Y.
A1  - Czudowska, Monika A.
A1  - Hofman, Albert
A1  - Uitterlinden, Andre G.
A1  - Wolfs, Roger C. W.
A1  - de Jong, Paulus T. V. M.
A1  - Oostra, Ben A.
A1  - Paterson, Andrew D.
A1  - Mackey, David A.
A1  - Bergen, Arthur A. B.
A1  - Reis, Andre
A1  - Hammond, Christopher J.
A1  - Vingerling, Johannes R.
A1  - Lemij, Hans G.
A1  - Klaver, Caroline C. W.
A1  - van Duijn, Cornelia M.
T1  - Common Genetic Determinants of Intraocular Pressure and Primary Open-Angle Glaucoma
JF  - PLoS Genetics
N2  - Intraocular pressure (IOP) is a highly heritable risk factor for primary open-angle glaucoma and is the only target for current glaucoma therapy. The genetic factors which determine IOP are largely unknown. We performed a genome-wide association study for IOP in 11,972 participants from 4 independent population-based studies in The Netherlands. We replicated our findings in 7,482 participants from 4 additional cohorts from the UK, Australia, Canada, and the Wellcome Trust Case-Control Consortium 2/Blue Mountains Eye Study. IOP was significantly associated with rs11656696, located in GAS7 at 17p13.1 (p = 1.4 x 10\(^{-8}\)), and with rs7555523, located in TMCO1 at 1q24.1 (p = 1.6 x 10\(^{-8}\)). In a meta-analysis of 4 case-control studies (total N = 1,432 glaucoma cases), both variants also showed evidence for association with glaucoma (p = 2.4 x 10\(^{-2}\) for rs11656696 and p = 9.1 x 10\(^{-4}\) for rs7555523). GAS7 and TMCO1 are highly expressed in the ciliary body and trabecular meshwork as well as in the lamina cribrosa, optic nerve, and retina. Both genes functionally interact with known glaucoma disease genes. These data suggest that we have identified two clinically relevant genes involved in IOP regulation.
KW  - expression
KW  - goldmann applanation tonometer
KW  - central corneal thickness
KW  - genome-wide scan
KW  - beaver-dam eye
KW  - to-disc ratio
KW  - onset
KW  - association
KW  - identification
KW  - population
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-131378
VL  - 8
IS  - 5
ER  -